Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The proportion of patients with sufficient baseline vitamin D levels (>30 ng/mL) did not differ significantly between groups (p = 0.28).

Source: 3.1. Demographic and Baseline Characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Clinical and Radiological Outcomes of Oral Bisphosphonate Therapy Combined with Conservative Treatment in Subchondral Bone Marrow Edema of the Knee: A Retrospective Cohort Study

Source: Article title.

Patients were eligible for inclusion if they were between 18 and 70 years of age, had MRI-confirmed subchondral bone marrow edema of the knee, received either conservative treatment alone or conservative treatment combined with oral bisphosphonate therapy, and had documented concordance between the anatomical location of BME on MRI and the site of predominant pain on physical examination, as recorded in the clinical notes.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Clinical and Radiological Outcomes of Oral Bisphosphonate Therapy Combined with Conservative Treatment in Subchondral Bone Marrow Edema of the Knee: A Retrospective Cohort Study

Cohort study · Journal of Clinical Medicine · 2026

Original publication title

Clinical and Radiological Outcomes of Oral Bisphosphonate Therapy Combined with Conservative Treatment in Subchondral Bone Marrow Edema of the Knee: A Retrospective Cohort Study

Goker Yurdakul; Murat Korkmaz; Irfan Karadak; Abdullah Iyigun; Muhammed Kazez; Nezih Yayli; Mustafa Fatih Erkoc; Fatih Golgelioglu

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background/Objectives:

Subchondral bone marrow edema (BME) of the knee often causes persistent pain despite conservative treatment, and evidence supporting oral bisphosphonates is limited. We compared conservative treatment alone with conservative treatment plus oral alendronate.

Methods:

This retrospective cohort study included 82 patients with MRI-confirmed subchondral BME of the knee treated between January 2020 and January 2025. Patients received conservative treatment alone (n = 44) or conservative treatment plus alendronate 70 mg weekly for three months (n = 38). Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were assessed at baseline and three months. Radiological response was assessed on follow-up MRI as the percentage reduction in BME area.

Results:

Both groups improved significantly at three months. The alendronate group showed greater reductions in VAS (4.0 ± 1.4 vs. 3.2 ± 1.3 points, p = 0.009) and total WOMAC scores (25.5 ± 8.9 vs. 19.8 ± 8.6 points, p = 0.002). Median time to full weight-bearing was shorter with alendronate (7 vs. 9 weeks, p = 0.021), and complete BME regression was more frequent (42.1% vs. 18.2%, Fisher’s exact p = 0.028). After adjustment for Kellgren: Lawrence grade, alendronate was associated with a favorable radiological response (OR = 3.66, 95% CI: 1.18 to 11.31, p = 0.024). No serious adverse events were recorded.

Conclusions:

Adding oral alendronate to conservative treatment was associated with greater clinical improvement, earlier full weight-bearing, and a more favorable radiological response at three months. Prospective randomized studies are needed to confirm these findings.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background/Objectives

Subchondral bone marrow edema (BME) of the knee often causes persistent pain despite conservative treatment, and evidence supporting oral bisphosphonates is limited. We compared conservative treatment alone with conservative treatment plus oral alendronate.

Source: Background/Objectives:

Abstract: Results

Both groups improved significantly at three months. The alendronate group showed greater reductions in VAS (4.0 ± 1.4 vs. 3.2 ± 1.3 points, p = 0.009) and total WOMAC scores (25.5 ± 8.9 vs. 19.8 ± 8.6 points, p = 0.002). Median time to full weight-bearing was shorter with alendronate (7 vs. 9 weeks, p = 0.021), and complete BME regression was more frequent (42.1% vs. 18.2%, Fisher’s exact p = 0.028). After adjustment for Kellgren: Lawrence grade, alendronate was associated with a favorable radiological response (OR = 3.66, 95% CI: 1.18 to 11.31, p = 0.024). No serious adverse events were recorded.

Source: Results

Abstract: Conclusions

Adding oral alendronate to conservative treatment was associated with greater clinical improvement, earlier full weight-bearing, and a more favorable radiological response at three months. Prospective randomized studies are needed to confirm these findings.

Source: Conclusions
Authors’ abstract

Background/Objectives:

Subchondral bone marrow edema (BME) of the knee often causes persistent pain despite conservative treatment, and evidence supporting oral bisphosphonates is limited. We compared conservative treatment alone with conservative treatment plus oral alendronate.

Methods:

This retrospective cohort study included 82 patients with MRI-confirmed subchondral BME of the knee treated between January 2020 and January 2025. Patients received conservative treatment alone (n = 44) or conservative treatment plus alendronate 70 mg weekly for three months (n = 38). Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were assessed at baseline and three months. Radiological response was assessed on follow-up MRI as the percentage reduction in BME area.

Results:

Both groups improved significantly at three months. The alendronate group showed greater reductions in VAS (4.0 ± 1.4 vs. 3.2 ± 1.3 points, p = 0.009) and total WOMAC scores (25.5 ± 8.9 vs. 19.8 ± 8.6 points, p = 0.002). Median time to full weight-bearing was shorter with alendronate (7 vs. 9 weeks, p = 0.021), and complete BME regression was more frequent (42.1% vs. 18.2%, Fisher’s exact p = 0.028). After adjustment for Kellgren: Lawrence grade, alendronate was associated with a favorable radiological response (OR = 3.66, 95% CI: 1.18 to 11.31, p = 0.024). No serious adverse events were recorded.

Conclusions:

Adding oral alendronate to conservative treatment was associated with greater clinical improvement, earlier full weight-bearing, and a more favorable radiological response at three months. Prospective randomized studies are needed to confirm these findings.

Publication and source details

Original title: Clinical and Radiological Outcomes of Oral Bisphosphonate Therapy Combined with Conservative Treatment in Subchondral Bone Marrow Edema of the Knee: A Retrospective Cohort Study

Goker Yurdakul; Murat Korkmaz; Irfan Karadak; Abdullah Iyigun; Muhammed Kazez; Nezih Yayli; Mustafa Fatih Erkoc; Fatih Golgelioglu

Journal of Clinical Medicine · 2026

* Correspondence: fatih.golgelioglu@bozok.edu.tr© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:50:40.668289+00:00

DOI: 10.3390/jcm15176529 · PMC13566092